HIGH FREQUENCY JET VENTILATION IN EXTREMELY PRETERM INFANTS -EXPERIENCE FROM WESTERN AUSTRALIA
Background: Bronchopulmonary dysplasia (BPD) is a significant health issue in preterm infants with gestation <32 weeks. Limited data exists on high frequency jet ventilation (HFJV) for reducing the risk of severe BPD in preterm infants.
Methods: Retrospective data analysis (1/2/2010-30/6/2014) on preterm infants managed with rescue HFJV.
Results: 50/1419 ventilated preterm infants <32 weeks required HFJV [Median (IQR) gestation, birth weight, postnatal age: 25.8 (25-28.3) weeks, 795 (636-1146) g, 11 (3.0-23.5) days respectively]. Indications for HFJV included air leaks and/or conventional/high frequency oscillatory ventilation with (1) Oxygenation failure: Mean airway pressure(MAP) >/=10 cm H 2 0 postsurfactant and fractional inspired oxygen (FiO 2 ) >0.3 and/or (2) Ventilation failure: PaCO 2 > 45; pH <7.2; tidal volume 4-6 ml/kg/breath. Three of these 50 infants required HFJV on more than one occasion. The median MAP and median FiO 2 before transferring them on HFJV were 10 (8-12) cmH 2 O and 0.42 (0.33-0.55) respectively. 15/50 infants had failed extubation at least once before HFJV was commenced. The median duration of HFJV was 194.5 hours. 26 infants (59%) were extubated to CPAP from HFJV. Twenty-one (55%) of the survivors in our cohort needed dexamethasone to facilitate weaning off respiratory support. Survival was 76% (38/50); 33/38 needed oxygen at 36 weeks PMA; 17 were discharged home on oxygen. Infants who died needed a higher MAP before transfer to HFJV, and their median duration of mechanical ventilation before HFJV was 100 hours shorter vs. those who survived. Conclusion: HFJV was feasible and safe in our cohort of extremely preterm infants. Randomised controlled trials need to assess the safety and efficacy of HFJV in reducing severe BPD in this population. 17/33 (51.51%) infants had congenital; 16/33 (48.48%) had secondary chylous effusion. 12/13 with hydrops had antenatal intercostal drains (ICD). 32/33 (96.96%) needed postnatal ICD (mean ICD's placed: 4). 25/33 (75.75%) underwent serial lung ultrasounds (>/= 2) and 30/33 (90.90%) had multiple chest xrays (>/= 5) for effusion monitoring. 6/33 (18.18%) were nil by mouth initially and 28/33 (84.84%) received medium chain triglyceride diet. 10/33 received intravenous immunoglobulin; 8/33 were treated with octreotide. 9/33 had proven late onset sepsis.
OUTCOMES OF NEONATAL CHYLOUS EFFUSIONS
28/33 survived, 5 died (3/5 due to hydrops sequelae). Of survivors, 27 needed ventilation, 24 required CPAP, and 7 developed bronchopulmonary dysplasia like symptoms. Median duration of hospital stay in survivors was 57 (32.25-70.75) days.
Ten (10/33) infants had proven syndromic association (VATER, VACTERAL, CHARGE, Noonan syndrome, 8P microdeletion, pulmonary lymphangiectasia, PHACE, distichiasis lymphedema syndrome, myotubular myopathy) and 4/33 were unclassified with multiple congenital anomalies. 4/10 with proven syndromic association died.
Conclusion: Neonatal chylous effusions are associated with significant morbidity and mortality, especially if associated with syndromes. Parental counselling should include this aspect. 
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